Document is current
Any future updates will be listed below
-
Authors
Gemesi, Kathrin https://orcid.org/0000-0002-5179-6366
Winkler, Stefanie
Schmidt-Tesch, Susanne
Schederecker, Florian https://orcid.org/0000-0002-5222-2348
Hauner, Hans https://orcid.org/0000-0002-1682-5088
Holzapfel, Christina https://orcid.org/0000-0002-0155-9338
- License Information
-
More Information
Article History
Received: 4 August 2023
Revised: 24 October 2023
Accepted: 7 November 2023
First Online: 28 November 2023
Competing interests
: KG, SW, SST and FS declare that they have no competing interest. HH is a member of the scientific advisory board of Oviva AG (Zurich, Switzerland). CH is a member of the scientific advisory board of the 4sigma GmbH (Oberhaching, Germany). HH and CH received speaker´s honoraria from Novo Nordisk.
: The study protocol has been approved by the Ethical Committee of the School of Medicine at the Technical University of Munich (number: 45/22 S-NP, date: March 3<sup>rd</sup> 2022). The study protocol has been submitted to BfArM (Federal Institute for Drugs and Medical Devices) for reviewing before starting the trial. The study is registered in the German Register of Clinical Studies (Registration number: DRKS00025291). Study participants had to give written informed consent prior to participation.
